Loading
Off-the-shelf T cells from healthy donors that recognise Epstein-Barr virus, used to treat virus-driven lymphomas after transplant; tabelecleucel was approved in Europe in 2022.
Some cancers are driven by viruses whose proteins make excellent T-cell targets. Banks of donor T cells selected for Epstein-Barr virus specificity and matched on HLA can be given off the shelf; tabelecleucel (Ebvallo) was approved in the European Union in 2022 for EBV-positive post-transplant lymphoproliferative disease that has failed other treatment. Similar products target cytomegalovirus and adenovirus after transplant, and EBV-directed cells are tested in nasopharyngeal carcinoma.
Donor T cells are expanded against viral antigens, banked by HLA type, and selected for each patient to share at least one restricting allele, then infused without lymphodepletion.
Tabelecleucel is a bank of donor T cells trained against Epstein-Barr virus, approved in Europe in 2022 as the first off-the-shelf T-cell therapy, for EBV-driven lymphoma after transplant when rituximab has failed.
Query for this technology: (TITLE:"Virus-specific T cells" OR ABSTRACT:"Virus-specific T cells") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Virus-specific T cells, not a curated reading list.
Shares A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failu, Tabelecleucel, A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases.
Shares Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
Shares Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
Shares Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
Shares A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failu, Tabelecleucel, Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
Shares Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
Shares Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.
Shares Allogeneic (off-the-shelf) cell therapy, Diffuse large B-cell lymphoma.